Testing lanreotide before pancreas surgery to prevent leaks
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests if a medicine called lanreotide, given before surgery, can prevent a common complication (pancreatic leak) after removing part of the pancreas. It is for people with pancreatic cancer or a growth that could become cancer who are scheduled for a specific type of pancreas surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You are scheduled to have surgery to remove the tail of the pancreas (distal pancreatectomy) within 60 days.
- You have not had radiation or a special treatment called PRRT for your pancreas in the past.
- You have not used a medicine like lanreotide (called a somatostatin analog) in the last 6 months.
- You do not have a condition that makes it hard for your body to absorb nutrients (malabsorption).
- You do not have severe liver problems and your kidney function is adequate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a drug called octreotide microspheres can help prevent a common complication after surgery to remove part of the pancreas. If you are scheduled for this type of surgery, this study may help reduce your risk of developing a leak from the pancreas.
This study looks at your immune system before pancreatic surgery to predict if you might develop a common post-surgery complication called a pancreatic leak (where digestive juices escape the pancreas). The goal is to see if simple blood tests before surgery can help doctors plan better care and reduce risks for future patients.
This trial tests a combination of a chemotherapy drug (irinotecan liposome) plus an immunotherapy drug (addebelizumab) given before surgery to people with pancreatic cancer that can be fully removed. The goal is to see if this treatment reduces the chance of the cancer coming back and improves outcomes.
This trial tests a new treatment, PTM-101, placed during a laparoscopy procedure for people with pancreatic cancer that can be removed with surgery. It aims to see if adding this treatment before standard chemotherapy helps improve outcomes.
This trial tests whether giving treatment before surgery helps people with pancreatic cancer that can be removed. The treatment is given before the operation, and the study checks if it is safe and effective.
This trial tests if a short course of radiation before surgery can lower the risk of a pancreatic leak (a common complication). It is for people who are overweight, older than 45, and have a small pancreatic duct.
Hear when a new Pancreatic Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.